A phase 2 study of Vactosertib in combination of Pomalidomide in Multiple Myeloma
Latest Information Update: 29 Mar 2022
Price :
$35 *
At a glance
- Drugs Pomalidomide (Primary) ; Vactosertib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 29 Mar 2022 According to a MedPacto company pipeline, the company has initiated this study.
- 29 Mar 2022 New trial record